Journal
JOURNAL OF BIOMOLECULAR SCREENING
Volume 13, Issue 9, Pages 870-878Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/1087057108323909
Keywords
beta-amyloid; calpain; high-throughput screen; Alzheimer's disease; neurodegeneration
Funding
- NINDS NIH HHS [U24 NS049339-01A1, U24 NS049339-04, U24 NS049339-03, U24 NS049339-03S1, U24 NS049339-02] Funding Source: Medline
Ask authors/readers for more resources
Calpain activation is hypothesized to be an early occurrence in the sequence of events resulting in neurogeneration, as well as in the signaling pathways linking extracellular accumulation of beta-amyloid (A beta) peptides and intracellular formation of neurofibrillary tangles. In an effort to identify small molecules that prevent neurodegeneration in Alzheimer's disease by early intervention in the cell death cascade, a cell-based assay in differentiated Sh-SY5Y cells was developed using calpain activity as a read-out for the early stages of death in cells exposed to extracellular A beta. This assay was optimized for high-throughput screening, and a library of approximately 120,000 compounds was tested. It was expected that the compounds identified as calpain inhibitors would include those that act directly on the enzyme and those that prevented calpain activation by blocking an upstream step in the pathway. In fact, of the compounds that inhibited calpain activation by A beta with IC50 values of <10 mu M and showed little or no toxicity at concentrations up to 30 mu M, none inhibit the calpain enzyme directly. (Journal of Biomolecular Screening 2008:870-878)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available